Hui R, Özgüroğlu M, Daniel D, et al. Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract PL 02.02.
Huidtoxiciteit zelden reden voor stoppen immuuntherapie bij kanker
sep 2020 | Immuuntherapie